Comparison • May 18, 2026

Semaglutide vs Tirzepatide vs Retatrutide

Semaglutide, tirzepatide, and retatrutide are not interchangeable search terms. Their receptor targets and evidence maturity differ.

Educational disclaimer: This article is for research literacy only and is not medical advice. It does not provide dosing, protocols, treatment plans, reconstitution instructions, sourcing instructions, or recommendations to buy or use any compound. Affiliate disclosure: I may earn a commission from links on this site, at no extra cost to you.

Free research kit

Save the COA and claim-checking prompts.

Get education-first checklists before you evaluate supplier pages or social claims.

Get the free research kit

Receptor target differences

Semaglutide is discussed as a GLP-1 receptor agonist. Tirzepatide is discussed as a dual GIP/GLP-1 receptor agonist. Retatrutide is commonly described in research as a multi-receptor incretin agonist involving GIP, GLP-1, and glucagon receptor activity.

That target-level difference is useful for research literacy, but it should not be turned into personal medical guidance.

Evidence maturity differs

Semaglutide and tirzepatide have approved-medicine contexts as well as research literature. Retatrutide remains a clinical-trial topic at the time of this education page.

Comparisons should separate approved labels, trial endpoints, adverse-event reporting, and online speculation.

How to avoid oversimplified claims

Avoid “best,” “strongest,” or “next big thing” framing unless a source defines the endpoint and evidence quality. A trial result for one population does not answer every use case.

This page is for source interpretation only. It is not a treatment recommendation or substitution guide.

Quick takeaways

1. Semaglutide, tirzepatide, and retatrutide have different receptor profiles

Semaglutide, tirzepatide, and retatrutide have different receptor profiles.

2. Approved and trial-stage evidence should not be blended

Approved and trial-stage evidence should not be blended.

3. Endpoint context matters

Endpoint context matters.

4. No personal treatment guidance is provided

No personal treatment guidance is provided.

Compare research supplier transparencyReview documentation, posted testing, and claim boundaries →View posted COA sourcesUse the checklist before trusting purity or content claims →See trusted sourcesAffiliate disclosure applies; independently verify every source →

Sources to start with

New education-first briefs weekly

Get the free research kit.

COA prompts, supplier due-diligence notes, and article drops. No dosing, protocols, or medical advice.